ArticleAdvances in therapy2026
Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe single-arm phase 1/2 LIBRETTO-001 trial demonstrated durable efficacy and a favorable safety profile with the selective RET inhibitor (RETi) selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC), regardless of prior non-RET-selective treatment. The aim of this study (RECALIB-RET), comparison of outcomes with first-line (1L) non-RET-selective therapy in a real-world external control arm to the LIBRETTO-001 selpercatinib-treated population, was precluded by a small real-world sample size. Therefore, we report European benchmark data, reflecting physician's choice of 1L therapy and treatment availability in routine clinical practice.
methodsThe study population comprised data from adult patients with RET fusion-positive, locally advanced/metastatic NSCLC who received ≥ 1 prior line of systemic non-RET-selective therapy, pooled across chart reviews from four European countries. Patient characteristics, biomarker testing and treatment patterns, clinical outcomes, and safety events during 1L therapy are reported.
resultsPatients in the RW benchmark population (n = 24) had a median age at 1L therapy initiation of 61.0 years (interquartile range 56.0-71.5); 58.3% were male and 41.7% were female, 95.8% had adenocarcinoma, and 91.7% had advanced-stage disease at diagnosis. Overall response and disease-control rates to 1L non-RET-selective therapy were 37.5% (95% confidence interval [CI] 18.8-59.4) and 58.3% (95% CI 36.6-77.9), respectively. Median progression-free survival was 5.4 months (95% CI 2.1-8.0). Median time between advanced disease diagnosis and biomarker testing (n = 21, 87.5%) was 17 days, with a median turnaround time for the results of 25 days; 70.8% (n = 17) initiated 1L treatment before receiving test results. Of 125 adverse events reported, 20 (16.0%) were grade ≥ 3.
conclusionOutcomes observed in the RECALIB-RET RW benchmark population reflect the limitations of non-selective RETi therapies in RET fusion-positive NSCLC, and reinforce the rationale for early use of targeted agents such as selpercatinib. Optimizing biomarker testing practices may enable earlier access to these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.